LATS1 sirna

LATS1 siRNA (Human)

Cat. Num. AAA8217577

• Gene Names: LATS1; wts; WARTS
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: LATS1; LATS1 siRNA (Human); WARTS; Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts; LATS1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: LATS1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 690

• Applicable Applications for LATS1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LATS1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for LATS1 sirna

siRNA to inhibit LATS1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 395394049
• NCBI GeneID: 9113
• NCBI Accession #: NP_001257448.1
• NCBI GenBank Nucleotide #: NM_001270519.1
• UniProt Accession #: O95835; Q6PKD0
• Molecular Weight: 76,193 Da
• NCBI Official Full Name: serine/threonine-protein kinase LATS1 isoform 2
• NCBI Official Synonym Full Names: large tumor suppressor kinase 1
• NCBI Official Symbol: LATS1
• NCBI Official Synonym Symbols: wts; WARTS
• NCBI Protein Information: serine/threonine-protein kinase LATS1
• UniProt Protein Name: Serine/threonine-protein kinase LATS1
• Protein Family: Serine/threonine-protein kinase
• UniProt Gene Name: LATS1
• UniProt Synonym Gene Names: h-warts
• UniProt Entry Name: LATS1_HUMAN

NCBI Description

The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. Two protein-coding transcripts and one non-protein coding transcript have been found for this gene. [provided by RefSeq, Jul 2012]

Uniprot Description

LATS1: an AGC kinase of the NDR family of kinases. Localized to the mitotic apparatus and specifically phosphorylated during mitosis. A likely tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDC2 kinase activity, causing G2 arrest. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. Complexes with CDC2 in early mitosis. LATS1-associated CDC2 has no mitotic cyclin partner and no apparent kinase activity. Binds phosphorylated zyxin, locating this protein to the mitotic spindle and suggesting a role for actin regulatory proteins during mitosis. Binds to and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. Knockout mice are susceptible to soft-tissue sarcomas and sensitive to chemical carcinogenesis. Human soft tissue sarcomas have downregulated, mutated, and/or hypermethylated LATS1. Transgenic expression blocks anchorage independent growth in culture and tumor growth in xenografts. Two alternatively spliced isoforms of the human proteinhave been described.

Protein type: Protein kinase, AGC; Kinase, protein; EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); Tumor suppressor; AGC group; NDR family

Chromosomal Location of Human Ortholog: 6q25.1

Cellular Component: spindle pole; microtubule organizing center; cytosol

Molecular Function: protein serine/threonine kinase activity; protein binding; magnesium ion binding; protein kinase binding; ATP binding

Biological Process: keratinocyte differentiation; mitosis; regulation of actin filament polymerization; hormone-mediated signaling; cell division; sister chromatid segregation; negative regulation of cyclin-dependent protein kinase activity; cytoplasmic sequestering of protein; regulation of protein complex assembly; G2/M transition of mitotic cell cycle; protein amino acid phosphorylation; positive regulation of peptidyl-serine phosphorylation